Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. - Wikidata - wikimedia - TriplyDB

Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.

Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.

http://www.wikidata.org/entity/Q34506608

about

New advances in targeted gastric cancer treatment Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.Development and strategies of VEGFR-2/KDR inhibitors.Angiogenesis and antiangiogenic agents in cervical cancer.Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors Rationale for targeting fibroblast growth factor receptor signaling in breast cancer Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis.VEGF/VEGFR signalling as a target for inhibiting angiogenesis.Fibroblast growth factors, old kids on the new block.Emerging drugs for the treatment of metastatic renal cancer.By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies.Tyrosine kinase inhibitors to treat liver cancer.Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy.Brivanib alaninate for cancer.A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.Brivanib: a review of development.Axitinib for the treatment of advanced non-small-cell lung cancer.Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.Review of angiogenesis in hepatocellular carcinoma.Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.Targeting FGFR in Squamous Cell Carcinoma of the Lung.Clinical trials of antiangiogenic therapy for hepatocellular carcinoma.A FGFR1 inhibitor patent review: progress since 2010.Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity.Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways.Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat.SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models.The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors.

P2860

Q26738548-2C3E13B0-3083-43EF-8F90-9AF6FB52840B Q26797535-8BB9C460-F626-46C3-9EBD-8431A2FF00BA Q26826817-94A4A0C9-51F9-49DC-9841-14D01281C705 Q27693185-5A285A3E-2448-4398-BAFC-41FCEA292F03 Q34082909-728F2682-2A6D-4BC6-B771-3C309FD5C651 Q34257497-C0F56AE8-2A56-4D10-9A23-B8A26D08E5A1 Q34436101-E90AB7B9-90B2-4315-B40B-FC4A0A625DB1 Q34655335-5BDE9C55-CA5F-40E6-8C68-74003BB9DEA3 Q35108333-9A0FFDF1-5069-4973-A5C5-92C61A0F238F Q35116704-ABFEAE62-02FB-4FAE-AC5D-B2D196ABD8A4 Q35131258-D04C1527-3DD8-4578-BDF5-DCC28165157E Q35141906-4FCE10CD-04C4-4C3F-92D2-6506AAD6E3C0 Q35759606-417E878F-089E-4DDF-92C4-507B7E82A8E7 Q36161541-795A8E0A-134A-4632-BCC9-BE150DD38159 Q36653663-27D0A807-9BA7-4AF9-9DCC-98150AAFD539 Q36677407-BD167E3A-1718-400A-A157-882E474FE241 Q36923642-ACFD589E-C274-4258-8BD6-F1D4B23F3345 Q36989925-51CEF249-24C5-4C2A-AC24-716468CB5FDC Q37039782-11FE6CB0-F7B1-4A9B-89F2-8AB87A224A70 Q37389768-5D0374C2-5854-4494-A816-1949807F12B1 Q37631288-20D56F52-79E1-4652-807F-DC2B6965A18A Q37632167-49582375-BCB6-4D3E-AEC3-CB5E78A3B66D Q37686529-E4E4393B-C18D-4761-9DDB-6CCD0025F0DB Q37849781-54069A9C-745B-4C07-8201-7F9F8DB349B0 Q37851518-4E2A5C0F-BD39-480F-8593-B298996DEE1C Q37976467-5BFCEC73-FDD3-47F9-95AE-65F9876DE682 Q38048883-A47DDE01-D9E0-4799-9CA9-50F66A674D85 Q38085684-DB38D074-4953-48A0-97C3-2C665F66D692 Q38151193-D47E33C0-2694-4CA9-94A3-236E6E826C74 Q38188582-8D87CC27-EE12-4A64-AB14-AB6E0890EF9F Q38354294-536A493B-AAB0-4B35-A3B7-957CAFA95B48 Q38690050-4CB814DC-D225-46A0-8AA6-29CA2103BA12 Q38743040-A7024412-A1C6-4639-8491-7891DE99F8DD Q38782612-F905FD00-AF7D-46D1-AF32-824A743E4A0D Q39062384-A3A02991-3B99-4F09-A5D5-18A7A05A6395 Q39431960-77DA607C-B8A3-483A-B6A0-0F25D61A1369 Q48431178-53097FBC-B044-458E-ADA9-E44B6920DFA1 Q50107409-5AEFDE60-C36C-4C70-A005-FC336EAD5C21 Q50951764-1453E944-4B3B-4259-AB66-14068373BF17 Q51375392-4B1D4442-A72D-4FC5-8352-2957589441F9

P2860

Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.

http://www.wikidata.org/entity/Q34506608

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Discovery and preclinical stud ...... tive potent VEGFR-2 inhibitor.

@ast

Discovery and preclinical stud ...... tive potent VEGFR-2 inhibitor.

@en

Discovery and preclinical stud ...... tive potent VEGFR-2 inhibitor.

@nl

type

label

Discovery and preclinical stud ...... tive potent VEGFR-2 inhibitor.

@ast

Discovery and preclinical stud ...... tive potent VEGFR-2 inhibitor.

@en

Discovery and preclinical stud ...... tive potent VEGFR-2 inhibitor.

@nl

prefLabel

Discovery and preclinical stud ...... tive potent VEGFR-2 inhibitor.

@ast

Discovery and preclinical stud ...... tive potent VEGFR-2 inhibitor.

@en

Discovery and preclinical stud ...... tive potent VEGFR-2 inhibitor.

@nl

P1433

Q34506608-5B7FCF4B-EFC2-4087-99A3-68BBEA69D255

P1476

Q34506608-10E6775C-79DD-42A7-B9A3-011039F370C1

P2093

Q34506608-08923434-F2ED-4863-989A-BBD86D67135E

Q34506608-10223338-824C-47F8-BBA1-40FBE11059A1

Q34506608-33161EE6-F951-4927-A8F5-09A1EBEDB98C

Q34506608-33533C0C-2FB6-4B66-9158-8844E8EF9729

Q34506608-4BA11967-372C-46DB-BACE-4398A52DD0E0

Q34506608-61D67F54-198A-4BA3-B4B7-64EB9A36FFE6

Q34506608-65957AC9-CE26-426C-B65D-C61A7FE1F9AF

Q34506608-67FB2345-F837-45BD-9EAA-F8B48C7D8408

Q34506608-68DAD019-E418-4F69-A916-261A7DBE441D

Q34506608-6CFEAB4F-1C73-471D-85B6-A6DAF3D71439

P304

Q34506608-E38D9B9A-6DC0-46EB-9849-40AABDAACDD7

P31

Q34506608-833914EB-7B33-42FE-A412-C2DCC454A8C9

P356

Q34506608-C836D992-8264-402B-A409-0140A4EBEB13

P407

Q34506608-D0B31F64-2CA0-425C-8D97-323726B84955

P433

Q34506608-696C08D1-35E7-46AA-A3FC-A6FE65842FC8

P478

Q34506608-9B045BBA-7EA6-4B00-9EF2-6486A48BA13E

P50

Q34506608-DFEF2BBA-E59F-486C-85A3-6163EAE5017D

P577

Q34506608-94B0FE00-72FC-4C71-9FC5-7C5983FC8A4E

P698

Q34506608-13DD04FA-B486-4342-868E-5BB0209AA4CA

P356

P1433

Journal of Medicinal Chemistry

P1476

Discovery and preclinical stud ...... ctive potent VEGFR-2 inhibitor

@en

P2093

Aberra Fura

http://www.w3.org/2001/XMLSchema#string

Amrita Kamath

http://www.w3.org/2001/XMLSchema#string

Arvind Mathur

http://www.w3.org/2001/XMLSchema#string

Barri Wautlet

http://www.w3.org/2001/XMLSchema#string

Celia D'Arienzo

http://www.w3.org/2001/XMLSchema#string

Daniel Kukral

http://www.w3.org/2001/XMLSchema#string

Donna Wei

http://www.w3.org/2001/XMLSchema#string

George Derbin

http://www.w3.org/2001/XMLSchema#string

Joel C Barrish

http://www.w3.org/2001/XMLSchema#string

Joseph Fargnoli

http://www.w3.org/2001/XMLSchema#string

P304

2143-2146

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM051106D

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16570908

http://www.w3.org/2001/XMLSchema#string